GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Genomma Lab Internacional SAB de CV (OTCPK:GNMLF) » Definitions » Piotroski F-Score

GNMLF (Genomma Lab InternacionalB de CV) Piotroski F-Score : 8 (As of Mar. 23, 2025)


View and export this data going back to 2012. Start your Free Trial

What is Genomma Lab InternacionalB de CV Piotroski F-Score?

Good Sign:

Piotroski F-Score is 8, indicates a very healthy situation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Genomma Lab InternacionalB de CV has an F-score of 8. It is a good or high score, which usually indicates a very healthy situation.

The historical rank and industry rank for Genomma Lab InternacionalB de CV's Piotroski F-Score or its related term are showing as below:

GNMLF' s Piotroski F-Score Range Over the Past 10 Years
Min: 5   Med: 6   Max: 8
Current: 8

During the past 13 years, the highest Piotroski F-Score of Genomma Lab InternacionalB de CV was 8. The lowest was 5. And the median was 6.


Genomma Lab InternacionalB de CV Piotroski F-Score Historical Data

The historical data trend for Genomma Lab InternacionalB de CV's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genomma Lab InternacionalB de CV Piotroski F-Score Chart

Genomma Lab InternacionalB de CV Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.00 5.00 7.00 6.00 8.00

Genomma Lab InternacionalB de CV Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.00 6.00 6.00 8.00 8.00

Competitive Comparison of Genomma Lab InternacionalB de CV's Piotroski F-Score

For the Drug Manufacturers - Specialty & Generic subindustry, Genomma Lab InternacionalB de CV's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genomma Lab InternacionalB de CV's Piotroski F-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Genomma Lab InternacionalB de CV's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Genomma Lab InternacionalB de CV's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec24) TTM:Last Year (Dec23) TTM:
Net Income was 22.421 + 34.478 + 33.522 + 22.703 = $113.1 Mil.
Cash Flow from Operations was -7.619 + 22.493 + 74.322 + 60.988 = $150.2 Mil.
Revenue was 252.908 + 253.901 + 258.631 + 223.707 = $989.1 Mil.
Gross Profit was 165.078 + 162.537 + 166.173 + 141.049 = $634.8 Mil.
Average Total Assets from the begining of this year (Dec23)
to the end of this year (Dec24) was
(1221.762 + 1284.132 + 1200.038 + 1193.9 + 1154.721) / 5 = $1210.9106 Mil.
Total Assets at the begining of this year (Dec23) was $1,221.8 Mil.
Long-Term Debt & Capital Lease Obligation was $242.9 Mil.
Total Current Assets was $594.5 Mil.
Total Current Liabilities was $323.8 Mil.
Net Income was 19.862 + 24.347 + 21.28 + -3.603 = $61.9 Mil.

Revenue was 231.802 + 254.931 + 252.211 + 207.677 = $946.6 Mil.
Gross Profit was 142.232 + 155.437 + 157.412 + 124.468 = $579.5 Mil.
Average Total Assets from the begining of last year (Dec22)
to the end of last year (Dec23) was
(1108.255 + 1211.893 + 1264.58 + 1267.476 + 1221.762) / 5 = $1214.7932 Mil.
Total Assets at the begining of last year (Dec22) was $1,108.3 Mil.
Long-Term Debt & Capital Lease Obligation was $249.4 Mil.
Total Current Assets was $628.6 Mil.
Total Current Liabilities was $390.1 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Genomma Lab InternacionalB de CV's current Net Income (TTM) was 113.1. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Genomma Lab InternacionalB de CV's current Cash Flow from Operations (TTM) was 150.2. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec23)
=113.124/1221.762
=0.09259086

ROA (Last Year)=Net Income/Total Assets (Dec22)
=61.886/1108.255
=0.05584094

Genomma Lab InternacionalB de CV's return on assets of this year was 0.09259086. Genomma Lab InternacionalB de CV's return on assets of last year was 0.05584094. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Genomma Lab InternacionalB de CV's current Net Income (TTM) was 113.1. Genomma Lab InternacionalB de CV's current Cash Flow from Operations (TTM) was 150.2. ==> 150.2 > 113.1 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec23 to Dec24
=242.85/1210.9106
=0.20055155

Gearing (Last Year: Dec23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec22 to Dec23
=249.433/1214.7932
=0.2053296

Genomma Lab InternacionalB de CV's gearing of this year was 0.20055155. Genomma Lab InternacionalB de CV's gearing of last year was 0.2053296. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec24)=Total Current Assets/Total Current Liabilities
=594.485/323.8
=1.83596356

Current Ratio (Last Year: Dec23)=Total Current Assets/Total Current Liabilities
=628.623/390.141
=1.61127131

Genomma Lab InternacionalB de CV's current ratio of this year was 1.83596356. Genomma Lab InternacionalB de CV's current ratio of last year was 1.61127131. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Genomma Lab InternacionalB de CV's number of shares in issue this year was 944.862. Genomma Lab InternacionalB de CV's number of shares in issue last year was 948.048. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=634.837/989.147
=0.64180248

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=579.549/946.621
=0.61222918

Genomma Lab InternacionalB de CV's gross margin of this year was 0.64180248. Genomma Lab InternacionalB de CV's gross margin of last year was 0.61222918. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec23)
=989.147/1221.762
=0.80960694

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec22)
=946.621/1108.255
=0.8541545

Genomma Lab InternacionalB de CV's asset turnover of this year was 0.80960694. Genomma Lab InternacionalB de CV's asset turnover of last year was 0.8541545. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+1+1+1+1+1+1+0
=8

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Genomma Lab InternacionalB de CV has an F-score of 8. It is a good or high score, which usually indicates a very healthy situation.

Genomma Lab InternacionalB de CV  (OTCPK:GNMLF) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Genomma Lab InternacionalB de CV Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Genomma Lab InternacionalB de CV's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Genomma Lab InternacionalB de CV Business Description

Traded in Other Exchanges
Address
Avenida Antonio Dovali Jaime, Number 70, Tower C, Floor 2, Office A. Colonia Santa Fe, Del. Alvaro Obregon, Mexico, MEX, MEX, CP 01210
Genomma Lab Internacional SAB de CV is a specialty and generic drug manufacturer. The company's stated goal is to improve and preserve the health and well-being of people through innovative, safe, and effective products. Genomma operates a wide variety of brands to serve different consumer needs, including pregnancy, pain medication, and deodorant. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.